A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Inclusion Criteria:

- Infant approximately 2 months of age (42 days to 90 days), inclusive

- In good health

Exclusion Criteria:

- Prior administration of any pneumococcal vaccine

- Known hypersensitivity to any component of the pneumococcal conjugate vaccine or any
diphtheria toxoid-containing vaccine

- Known or suspected impairment of immunological function

- History of congenital or acquired immunodeficiency (eg, splenomegaly)

- Mother has documented human immunodeficiency virus (HIV) infection

- Mother has documented hepatitis B surface antigen-positive test result

- Known or history of functional or anatomic asplenia

- History of failure to thrive

- History of a coagulation disorder

- History of autoimmune disease

- Known neurologic or cognitive behavioral disorder

- Expects to require systemic corticosteroids within 30 days after each vaccination
during the trial

- Prior administration of a blood transfusion or blood products, including
immunoglobulin

- Participated in another clinical trial of an investigational product

- History of invasive pneumococcal disease or known history of other culture-positive
pneumococcal disease